FDA Biosimilars Guidances Stuck in Review, But That Isn’t Stopping Progress

Drug Industry Daily
A A
Even though the FDA hasn’t released details on how its abbreviated approval pathway for biosimilars will work, the agency has already held 21 pre-IND meetings on 11 reference biologics and received seven INDs, said Leah Christl, CDER’s associate director for biosimilars.

To View This Article:

Login

Subscribe To Drug Industry Daily